REG - Futura Medical PLC - Futura Remuneration, Options & Total Voting Rights
12/01/2023 11:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230112:nRSL5589Ma&default-theme=true
RNS Number : 5589M Futura Medical PLC 12 January 2023
12 January 2023
Futura Medical plc
("Futura" or the "Company")
Remuneration of Non-Executive Directors, Grant of Options and Total Voting
Rights
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products based on its proprietary, transdermal DermaSys® drug
delivery technology and currently focused on sexual health and pain, announces
the issue of 87,430 new ordinary shares of 0.2 pence each ("Ordinary Shares")
in respect of the 2022 remuneration of its Non-Executive Directors and a grant
of 4,444,942 options over Ordinary Shares ("Options") to employees and
Directors.
Remuneration of Non-Executive Directors
In accordance with the terms of their service agreements, the Non-Executive
Directors receive 25-30 per cent of their remuneration in the form of Ordinary
Shares. For 2022, these were issued at 36.36 pence per share, being the
average closing mid-market price of the last 10 trading days of 2021 (as
announced via RNS on 13 January 2022).
The 87,430 new Ordinary Shares shall rank pari passu with the existing issued
Ordinary Shares of the Company and have been issued as follows:
Director Number of Ordinary Shares issued for 2022 remuneration Total number of ordinary shares held Percentage of the Company's resulting issued share capital
John Clarke 44,560 795,100 0.28%
Jeff Needham 16,344 16,344 0.01%
Andrew Unitt 26,526 26,526 0.01%
The shares element of the Non-Executive Directors' remuneration for 2023 will
be awarded at 51.50 pence per Ordinary Share, being the average closing
mid-market price of the last 10 trading days of 2022. The Non-Executive
Directors will receive these shares in January 2024.
Grant of Options
The Company has granted a total of 4,444,942 Options of which 1,985,626 have
been awarded to Directors as detailed below.
All Options have been granted under existing schemes and vest equally over 3
years to January 2025 with 25% of the Options granted with immediate vesting.
The main condition is that the individual remains an employee or Director at
the time of vesting.
Director Number of Options granted Exercise price Total number of Options held following grant
James Barder 540,716 0.2p 2,085,716
Angela Hildreth 472,340 0.2p 1,508,340
John Clarke 463,343 0.2p 463,343
Ken James 509,227 0.2p 1,945,227
Total Voting Rights
Application has been made to the London Stock Exchange and it is anticipated
that trading of the new Ordinary Shares will commence on AIM at 8:00am on 17
January 2023.
Immediately following the above issue, the Company will have 288,133,957
ordinary shares in issue, each carrying one voting right. Since the Company
currently holds no shares in treasury, the total number of voting rights in
the Company is therefore 288,133,957 and this figure may be used by
Shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change in
their interest in, the share capital of the Company under the FCA's Disclosure
Guidance and Transparency Rules.
Further details are contained within the notifications below, made in
accordance with Article 19 of the EU Market Abuse Regulation 596/2014. Full
details of the Non-Executive Directors' remuneration will be included in the
Company's Annual Report & Accounts.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com (http://www.futuramedical.com/)
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Current therapeutic areas are sexual
health, including erectile dysfunction, and pain relief. Development and
commercialisation strategies are designed to maximise product differentiation
and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a breakthrough treatment
for erectile dysfunction ("ED") through a unique evaporative mode of action.
Futura has previously conducted a Phase 3 study using MED3000 in ED, referred
to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre,
randomised, double blind, placebo-controlled, home use, parallel group study
delivering highly statistically significant results compared to pre-treatment
baseline, using measures IIEF-EF, SEP2 and SEP3 (internationally accepted
clinical trial endpoints in ED) with over 60% of patients experiencing a
clinically meaningful improvement in their ED.
MED3000 is CE marked in Europe and CA marked in the UK as a clinically
proven topical treatment for adult men with erectile dysfunction under the
brand Eroxon™ with a key claim of "Helps you get an erection within 10
minutes".
Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com)
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name John Clarke
2 Reason for the notification
a) Position/status Director/ PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Futura Medical plc
b) LEI 21380053QLT46UNV2303
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Ordinary shares of 0.2p each
Identification code
GB0033278473
b) Nature of the transaction Issue of shares
c) Price(s) and volume(s)
Price(s) Volume(s)
36.36 pence 44,560
d) Aggregated information
- Aggregated volume
Not applicable
- Price
e) Date of the transaction 11 January 2023
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregated volume
- Price
Not applicable
e)
Date of the transaction
11 January 2023
f)
Place of the transaction
Outside of trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Jeff Needham
2 Reason for the notification
a) Position/status Director/ PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Futura Medical plc
b) LEI 21380053QLT46UNV2303
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Ordinary shares of 0.2p each
Identification code
GB0033278473
b) Nature of the transaction Issue of shares
c) Price(s) and volume(s)
Price(s) Volume(s)
36.36 pence 16,344
d) Aggregated information
- Aggregated volume
Not applicable
- Price
e) Date of the transaction 11 January 2023
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregated volume
- Price
Not applicable
e)
Date of the transaction
11 January 2023
f)
Place of the transaction
Outside of trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Andrew Unitt
2 Reason for the notification
a) Position/status Director/ PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Futura Medical plc
b) LEI 21380053QLT46UNV2303
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Ordinary shares of 0.2p each
Identification code
GB0033278473
b) Nature of the transaction Issue of shares
c) Price(s) and volume(s)
Price(s) Volume(s)
36.36 pence 26,526
d) Aggregated information
- Aggregated volume
Not applicable
- Price
e) Date of the transaction 11 January 2023
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregated volume
- Price
Not applicable
e)
Date of the transaction
11 January 2023
f)
Place of the transaction
Outside of trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name James Barder
2 Reason for the notification
a) Position/status Director/ PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Futura Medical plc
b) LEI 21380053QLT46UNV2303
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Options over Ordinary shares of 0.2p each
Identification code
GB0033278473
b) Nature of the transaction Grant of Options over Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
nil 540,716
d) Aggregated information
- Aggregated volume
Not applicable
- Price
e) Date of the transaction 10 January 2023
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregated volume
- Price
Not applicable
e)
Date of the transaction
10 January 2023
f)
Place of the transaction
Outside of trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Angela Hildreth
2 Reason for the notification
a) Position/status Director/ PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Futura Medical plc
b) LEI 21380053QLT46UNV2303
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Options over Ordinary shares of 0.2p each
Identification code
GB0033278473
b) Nature of the transaction Grant of Options over Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
nil 472,340
d) Aggregated information
- Aggregated volume
Not applicable
- Price
e) Date of the transaction 10 January 2023
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregated volume
- Price
Not applicable
e)
Date of the transaction
10 January 2023
f)
Place of the transaction
Outside of trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name John Clarke
2 Reason for the notification
a) Position/status Director/ PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Futura Medical plc
b) LEI 21380053QLT46UNV2303
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Options over Ordinary shares of 0.2p each
Identification code
GB0033278473
b) Nature of the transaction Grant of Options over Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
nil 463,343
d) Aggregated information
- Aggregated volume
Not applicable
- Price
e) Date of the transaction 10 January 2023
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregated volume
- Price
Not applicable
e)
Date of the transaction
10 January 2023
f)
Place of the transaction
Outside of trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Ken James
2 Reason for the notification
a) Position/status Director/ PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Futura Medical plc
b) LEI 21380053QLT46UNV2303
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument
Options over Ordinary shares of 0.2p each
Identification code
GB0033278473
b) Nature of the transaction Grant of Options over Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
nil 509,227
d) Aggregated information
- Aggregated volume
Not applicable
- Price
e) Date of the transaction 10 January 2023
f) Place of the transaction Outside of trading venue
d)
Aggregated information
- Aggregated volume
- Price
Not applicable
e)
Date of the transaction
10 January 2023
f)
Place of the transaction
Outside of trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHGPUCUGUPWGGPRecent news on Futura Medical
See all newsREG - Futura Medical PLC - Results for the Year ended 31 December 2023
AnnouncementREG - Futura Medical PLC - Notice of Results and Investor Presentation
AnnouncementRCS - Futura Medical PLC - Eroxon to be available on prescription
AnnouncementREG - Futura Medical PLC - Trading Update
AnnouncementREG - Futura Medical PLC - Appointment of Joint Corporate Broker
Announcement